Published in J Chemother on August 01, 2009
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis (1996) 2.34
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Rhinovirus bronchiolitis and recurrent wheezing: 1-year follow-up. Eur Respir J (2011) 2.25
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Thrombosis in the portal venous system after elective laparoscopic splenectomy. Surg Endosc (2004) 1.92
Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4. Cell (1986) 1.82
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol (2000) 1.74
Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. Dig Liver Dis (2005) 1.58
A three-year diagnostic and epidemiological study on viral infantile diarrhoea in Rome. Epidemiol Infect (1988) 1.57
SPECT during sleepwalking. Lancet (2000) 1.54
Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci U S A (1999) 1.53
The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS (1999) 1.52
Outpatient parenteral antibiotic therapy for bone and joint infections: an italian multicenter study. J Chemother (2007) 1.50
OAS1: a multiple sclerosis susceptibility gene that influences disease severity. Neurology (2010) 1.45
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.43
Hepatitis C virus treatment revolution: need for close monitoring. Clin Microbiol Infect (2014) 1.43
Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatr (1999) 1.41
Cytomegalovirus encephalitis in two patients with AIDS receiving ganciclovir for cytomegalovirus retinitis. J Infect (1994) 1.41
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ (1994) 1.41
Detection of respiratory viruses in the 2009 winter season in Rome: 2009 influenza A (H1N1) complications in children and concomitant type 1 diabetes onset. Int J Immunopathol Pharmacol (2011) 1.40
False positives and false negatives: is the answer relatively simple? Acta Psychiatr Scand (2012) 1.39
Anticardiolipin antibody in the acquired immunodeficiency syndrome: a marker of Pneumocystis carinii infection? J Infect (1989) 1.39
Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med (1999) 1.38
Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infants. Arch Dis Child (2009) 1.37
Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients. Am J Gastroenterol (2001) 1.31
Cerebrospinal fluid cytokines in patients with tuberculous meningitis. Clin Immunol Immunopathol (1997) 1.29
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
A seven-year prospective study on spondylodiscitis: epidemiological and microbiological features. Infection (2010) 1.21
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother (2000) 1.18
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med (2007) 1.17
Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis (1991) 1.15
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.14
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations. J Med Virol (2001) 1.14
Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase. AIDS Res Hum Retroviruses (1996) 1.14
Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J (1992) 1.12
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol (1999) 1.12
Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res Hum Retroviruses (1998) 1.10
A modified umbilical incision for specimen extraction after laparoscopic abdominal surgery. Surg Endosc (2007) 1.09
New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res (1996) 1.09
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol (2011) 1.09
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS (2000) 1.07
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS (2001) 1.07
Precise measurement of the e+e- --> pi+pi-(gamma) cross section with the initial state radiation method at BABAR. Phys Rev Lett (2009) 1.07
Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol (2000) 1.07
Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood (1991) 1.07
Dynamics of persistent TT virus infection, as determined in patients treated with alpha interferon for concomitant hepatitis C virus infection. J Virol (2001) 1.06
C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol (1997) 1.05
Measurement of |V(cb)| and the form-factor slope in B --> Dl- nu(l) decays in events tagged by a fully reconstructed B meson. Phys Rev Lett (2010) 1.05
Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS (2001) 1.04
Generation of a soluble IFN-gamma inducer by oxidation of galactose residues on macrophages. Cell Immunol (1985) 1.03
A protective effect of the Mediterranean diet for cutaneous melanoma. Int J Epidemiol (2008) 1.02
Antigen-specific human T-cell hybridomas with helper activity. Proc Natl Acad Sci U S A (1982) 1.02
Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol (1994) 1.02
Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis (1999) 1.01
Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis. Clin Exp Immunol (1998) 1.01
[Laparoscopic right hemicolectomy with intracorporeal anastomosis. Technical aspects and personal experience]. Minerva Chir (2003) 0.99
L-carnitine deficiency in AIDS patients. AIDS (1992) 0.99
Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients. AIDS (1999) 0.99
Paramyosin of Echinococcus granulosus: cDNA sequence and characterization of a tegumental antigen. Parasitol Res (1993) 0.99
The relation between dietary habits and urinary levels of 3-phenoxybenzoic acid, a pyrethroid metabolite. Food Chem Toxicol (2012) 0.98
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol (2002) 0.98
Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol (1994) 0.98
ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era. Qual Life Res (2006) 0.97
Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood (1997) 0.96
Induction of alpha interferon by membrane interaction between viral surface and peripheral blood mononuclear cells. Proc Soc Exp Biol Med (1985) 0.96
Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain (2003) 0.96
Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response. Clin Exp Immunol (2006) 0.96
Inosine pranobex and zidovudine metabolism. Lancet (1989) 0.96
Search for the rare leptonic decay B--->tau-nutau. Phys Rev Lett (2005) 0.96
Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res Hum Retroviruses (1992) 0.95
Rapid spread of the novel respiratory syncytial virus A ON1 genotype, central Italy, 2011 to 2013. Euro Surveill (2014) 0.95
Evidence for shared epitopes between cardiolipin and Pneumocystis carinii. J Infect Dis (1989) 0.95
Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther (2007) 0.94
HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naïve subjects. J Clin Microbiol (2011) 0.94
Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci (2013) 0.94